Tony's Diary Package — page 654

Company Platform Non-clinical results #who got Protection from Protection from Efficacy against vaccine hospitalization COVIDseveredz --_--milder COVID from COVID-19 (some at home) mRNA-1273 Neutralizing Abs; Strong 97% (1 in vaccine I 97% (30 cases in MRNA in lipid Thi CD4+, CD8+; arm after 2nd --_| placebo arm; 0 in MOderNd panoparticle protection from dose vaccine reported but challenge (macaques) hospitalized) 1 severe per FDA) BNT162b2 I Neutralizing Abs; Strong I~18,600 I 100% 100% (9 cases in I 95% MRNA in lipid Tht CD4+, CD8+; placebo arm; 0 in nanoparticle protection from vaccine- 1 initially challenge (macaques) severe but not) JNJ-78436725 I Neutralizing Abs; Strong I~22,000 I 100% 85.4% across 3 sites I 72% US; 61% Non-replicating Thi CD4+>Th2; CD8+; I US, Latin (7 deaths, 16 Latin America; human challenge protection _| America, hospitalizations, all I 65% S. Africa adenovirus/ONA (macaque) S.Africa in placebo arm) (96% 81.351) 'AZO 1222 I Neutralizing Abs; Strong I ~8588 100% 100% (15 in placebo I 70% overall; % Non-replicating Thi CD4+ > Th2; CD8+; = all hospitalized; 0 I 76% 1 dose; s. Astrazeneca I Chimp Adenovirus- protection from in vaccine) Africa trial DNA challenge (macaques) halted for mild NVX-CoVv2373 I Neutralizing Abs; Strong I ~8833 100% 100% (10 severe in I 96.4% UK]89% NOVAVAX spike protein/RBD + Thi CD4 > Th2; challenge I (Phase 3 placebo in UK/SA; 0 I B117 UK; 55% Matrix M adjuvant protection (macaques) _| UK; 2b SA) in vaccine) 'SA (94% 81351) Sputnik y I A@26and ads I NAbs;IFN-ysecretion I~14964 -- I 100% 100% (20 in placebo; I 91.6% adenovirus/ONA PMBCS, cellular response vaccine)